Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of NHL35700 in adults with schizophrenia
CTR20262176Phase 3Active
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NHL35700 in schizophrenia, sponsored by Jiangsu Nhwa Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
NHL35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20262176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262176.